Monthly Archives - January 2024

08Jan

Gentex Announces eSight Acquisition Set to Showcase Advanced Vision Tech at CES 2024

Gentex Corporation (NASDAQ: GNTX) announced today the asset acquisition of eSight, a leading provider of vision enhancement technologies, to develop and manufacture the next generation of mobile electronic eyewear designed to help people living with visual impairments. Gentex will prominently feature eSight’s next-gen technology at the Consumer Electronics Show (CES) 2024. Gentex is a technology company and a long-time supplier of electro-optical products for the global automotive, aerospace, and fire protection industries. Read more >>
Portfolio News
Read more...
08Jan

EcoSoul: Making a Difference

Noida-based D2C-first company EcoSoul sells eco-friendly home essentials. And it doesn’t use paper to make them…In just three years since its inception, sustainable home essentials brand EcoSoul Home has sold 967,000 products in over five countries to almost a lakh customers. In the process, the company has contributed to reducing 1,327,528 pounds of plastic, and 1,327,528 carbon emissions. It’s all thanks to the unique business idea of co-workers turned co-founders Rahul Singh and Arvind Ganesan who found a way to...
Portfolio News
Read more...
04Jan

Immusoft To Present on ISP-001 Clinical Trial at WORLDSymposium™ 2024 Conference

Immusoft Corporation, a cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that it will present at the upcoming WORLDSymposium 2024 Conference, held in San Diego, February 4-9, 2024. WORLDSymposium is the largest international gathering of lysosomal disease researchers. Immusoft is developing a new modality of gene encoded medicine that holds the promise of being durable and redosable. The Company’s lead investigational drug candidate ISP-001, is a first-in-class investigational treatment for mucopolysaccharidosis type I...
Portfolio News
Read more...
02Jan

Companies to Watch in 2024

For the past ten years, Life Science Nation (LSN) has built a global partnering platform that matches scientist-entrepreneurs and fundraising CEOs with capital, licensing, and product collaboration partners. In that time, LSN has learned so much about what makes a compelling fit for our buy-side partners. I have had discussions with hundreds of investors. I always want to understand how their investment theme of seeking early-stage technology assets is balanced with the risk of going early. Unsurprisingly, it’s complicated, but it typically...
Portfolio News
Read more...